EyePoint Pharmaceuticals News and Activities
Presence
EyePoint Pharmaceuticals develops and commercializes treatments for eye diseases. Its products and drug delivery technologies serve ophthalmologists, retina specialists, and patients who need long-lasting care for serious eye conditions.
EyePoint Pharmaceuticals products and services overview:
- Eye disease drugs
- Retinal treatments
- Drug delivery systems
- Ophthalmic implants
Revenue: ~$44 million
Employees: 160
Headquarters: Watertown, United States (USA)
EyePoint Pharmaceuticals is one of the...
EyePoint Pharmaceuticals is a company listed under the stock ticker EYPT (US).
Executives
View the org chart displaying its 20 main executives
Most searched biographies at EyePoint Pharmaceuticals
- Jay Duker, President, Chief Executive Officer and Director
- Wendy DiCicco, Director
- Nancy Lurker, Executive Vice Chairman of the Board
Popular executive movements at EyePoint Pharmaceuticals
- Michael Campbell has joined the company as Chief Commercial Officer (posted on February 18 2026).
Create your alert
to follow the executive moves at EyePoint Pharmaceuticals.
Medical Equipment
EyePoint Pharmaceuticals has 1,235 competitors including Thermo Fisher Scientific (United States (USA)), Medtronic (Ireland) and Philips (Netherlands).
Popular M&A news in Medical Equipment
- Bridgepoint has announced the acquisition of Obagi Medical Products (posted on June 4 2026).
- Niowave has just announced a $70 Million fundraising (posted on June 2 2026).
- The new name of Edap Tms is FocalTherics. (posted on June 1 2026).
Popular contacts in Medical Equipment
News
Press releases by EyePoint Pharmaceuticals
- EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - EyePoint, Inc.
- EyePoint Announces Participation at Upcoming Investor Conferences - EyePoint, Inc.
- EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data - EyePoint, Inc.
- EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments - EyePoint, Inc.
- EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026 - EyePoint, Inc.
- EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - EyePoint, Inc.
- EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - EyePoint, Inc.
- EyePoint Initiates Phase 3 Trials of Duravyu for DME
- EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments - EyePoint, Inc.
- EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema - EyePoint, Inc.
- View more press releases Close
Social media about EyePoint Pharmaceuticals
- EyePoint Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
- EyePoint Pharmaceuticals on LinkedIn, X (Twitter) & YouTube
